Hepatitis A Virus Core Protein P2C
recombinant, E. coli
For in vitro use only!
Shipping: shipped on gel packs
Storage Conditions: store at -20 °C
avoid freeze/thaw cycles
Shelf Life: 12 months
Molecular Weight: 38.5 kDa
Purity: > 90 % (SDS-PAGE)
Form: liquid (Supplied in 10 mM CBB pH 9.6, 0.1% SDS and 50% glycerol)
Recombinant HAV-P2C may be used in ELISA and Western blots, excellent for detection of HAV with minimal specificity problems.
The E. coli derived recombinant 38.5 kDa protein contains the P2C immunodominant regions, amino acids 1121-1234. HAV core proteins are purified by proprietary chromatographic techniques.
Background: Forty-two antigenic domains were identified across the hepatitis A virus (HAV) polyprotein by using a set of 237 overlapping 20-mer synthetic peptides spanning the entire HAV polyprotein and a panel of serum samples from acutely HAVinfected patients. The term antigenic domain is used in this study to define a protein region spanned with consecutive overlapping immunoreactive peptides. Nineteen antigenic domains were found within the structural proteins, and 22 were found within the nonstructural proteins, with 1 domain spanning the junction of VP1 and P2A proteins. Five of these domains were considered immunodominant, as judged by both the breadth and the strength of their immunoreactivity. One domain is located within the VP2 protein at position 57-90 aa. A second domain, located at position 767-842 aa, contains the C-terminal part of the VP1 protein and the entire P2A protein. A third domain, located at position 1403-1456 aa, comprises the C-terminal part of the P2C protein and the N-terminal half of the P3A protein. The fourth domain, located at position 1500-1519 aa, includes almost the entire P3B, and the last domain, located at position 1719-1764 aa, contains the C-terminal region of the P3C protein and the N-terminal region of the P3D protein. It is interesting to note that four of the five most immunoreactive domains are derived from small HAV proteins and/or encompass protein cleavage sites separating different HAV proteins.
Specificity: Immunoreactive with sera of HAV-infected individuals.
BIOZ Product Citations:
Please click the arrow on the right to expand the citation list. Click publication title for the full text.
Kanda et al. (2004) Interference of hepatitis A virus replication by small interfering RNAs. Biochem. Biophys. Res. Commun. 318:341.
Kanda et al. (2003) Hepatitis A virus VP3 may activate serum response element associated transcription. Scand. J. Gastroenterol. 38:307.
Hu et al. (2002) Mutational characteristics in consecutive passage of rapidly replicating variants of hepatitis A virus strain H2 during cell culture adaptation. World J. Gastroenterol. 8:872.
Emerson et al. (2002) Identification of VP1/2A and 2C as virulence genes of hepatitis A virus and demonstration of genetic instability of 2C. J. Virol. 76:8551.
Frings et al. (2001) Adaptation of primate cell-adapted hepatitis A virus strain HM175 to growth in guinea pig cells is independent of mutations in the 5' nontranslated region. J. Gen. Virol. 82:597.